SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Co-Diagnostics, Inc. with Losses of $100,000 to Contact the Firm
The Californer/10205461

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ: CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before October 17, 2022.

If you are a shareholder who suffered a loss, click here to participate.

More on The Californer

• US Van Rental Expands Group Transportation Services Across Los Angeles
• GIFTAWAY's Wood Wick Candle Collection Sets the Tone for the New Year
• Inclusive Hip-Hop Dance Class with Culture Shock Celebrates Movement Without Limits
• Long Beach: El Dorado Nature Center to Hold New Year, New Use Recycling Drive
• UK Financial Ltd Executes Compliance Tasks Ahead Of First-Ever ERC-3643 Exchange-Traded Token, SMCAT & Sets Date For Online Investor Governance Vote

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Co-Diagnostics suffered from a sharp drop in demand for its Logix Smart™ COVID-19 Test, a problem that persisted throughout the quarter ending June 30, 2022. Despite this drop in demand, the Company made positive statements about the consumer demand for its product. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Co-Diagnostics, investors suffered damages.

More on The Californer

• "Has Your Book Been Suppressed?" Widespread Censorship by Amazon, Google, and Meta
• TheOneLofi2: New Home for Chill Lo-Fi Hip Hop Beats Launches on YouTube
• Long Beach Health Department Announces Conclusion of Healthy Active Long Beach Program Following Loss of Federal Funding
• Eric Galuppo Highlights Structural Growth Risk Facing Service Companies
• City of Long Beach Invites Public to Share Their Priorities for the 2027 City Budget at Upcoming Community Meetings

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

---

Show All News | Report Violation